Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis

Suggested Citation

Khuntha S., Prawjaeng J., Ponragdee K., Sanmaneechai O., Srinonprasert V., Leelahavarong P. Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis. Applied Health Economics and Health Policy (2024). doi:10.1007/s40258-024-00915-y Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/101488

Availability

Collections